Synthesis and Bioactivity of New Finasteride Conjugate

April 2011 in “ Bioorganic & Medicinal Chemistry Letters ”

Zhao Shuang, Wu Jiazhen, Yang Li-juan, Li Zhuo, Yu Dahai, Li JinFeng, Yu Jing, Liang Yongtao, Wang En-si, Fang Xue-xun

Finasteride 5α-reductase benign prostate hyperplasia immune response Polimod Propecia

Studysummary In this study, a new Finasteride conjugate showed stronger inhibition of 5α-reductase and similar reduction of prostate hyperplasia in rats compared to Finasteride, with potentially improved toxicity.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study aimed to develop a new Finasteride conjugate for the treatment of benign prostate hyperplasia (BPH). The new compound showed better inhibition of 5α-reductase activity in vitro and improved outcomes in vivo in a rat model with BPH. The rats in the Finasteride conjugate group also showed better vital signs than those in the Finasteride group. The results suggest that the Finasteride conjugate may have other functions on animals than Finasteride, possibly with improved immune response or reduced toxicity. Further research is needed to investigate the immune modulation activity of the Finasteride conjugate and compare it with Polimod.

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research An Overview on 5α-Reductase Inhibitors

219 citations , October 2009 in “Steroids”

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

research Anabolic Effects of Testosterone Are Preserved During Inhibition of 5α-Reductase

42 citations , May 2007 in “Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism”

In this animal study, administering testosterone alongside a 5α-reductase inhibitor counteracted testosterone's effects on prostate enlargement while preserving its beneficial effects on muscle and bone.

research Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia

52 citations , February 2006 in “Current pharmaceutical design”

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

1054 citations , February 1998 in “The New England Journal of Medicine”

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.